Download Files:
Metformin
$32 – $80
Products Details
Product Description
– Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].
Web ID
– HY-B0627
Storage Temperature
– -20°C (Powder, protect from light, stored under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C4H11N5
Citations
– Acta Pharmacol Sin. 2021 Sep 3.|Ann Transl Med. 2021 Oct;9(20):1547.|Antioxidants. 2020 Oct 28;9(11):1057.|Arch Biochem Biophys. 2022 Jun 15;722:109216.|Biochem Bioph Res Co. 2020 Dec 17;533(4):665-671.|Biochem Cell Biol. 2023 Aug 21.|Biochem Pharmacol. 2023 Jun 6, 115636.|Biofactors. 2023 Mar 16.|Biomolecules. 2022 Mar 9;12(3):422.|bioRxiv. 2023 May 12.|Cancer Lett. 2022 Feb 2;215582.|Cell Commun Signal. 2023 May 4;21(1):99.|Cell Death Differ. 2023 Jun 19.|Cell Death Dis. 2022 Apr 20;13(4):384.|Cell Mol Life Sci. 2023 Sep 9;80(10):283.|Cell Regen. 2022 May 5;11(1):19.|Cell Rep. 2022 Nov 22;41(8):111707.|Cell Res. 2023 Jul 17.|Circulation. 2022 Nov 30.|Clinical Cancer Drugs. 2020 Apr.|Emerg Microbes Infect. 2022 Feb 22;1-34.|Environ Toxicol. 2021 Aug 25.|Eur J Pharmacol. 2023 Aug 1;175942.|Eur J Pharmacol. 2023 Feb 3;943:175569.|Front Immunol. 2016 Dec 12;7:597. |Front Oncol. 2021 Nov 22;11:762523.|Genes (Basel). 2022 Dec 16;13(12):2384.|Hum Reprod. 2020 May 1;35(5):1145-1158.|Int Immunopharmacol. 2023 Sep 15;124(Pt A):110905.|Int J Mol Sci. 2023, 24(1), 343.|Int J Morphol. 40(5):1152-1164, 2022.|J Med Chem. 2022 Aug 29.|J Orthop Surg Res. 2023 Nov 4;18(1):831.|Liver Int. 2023 May 19.|Mol Med Rep. 2023 Jan;27(1):17.|Nat Commun. 2021 Aug 24;12(1):5106.|Onco Targets Ther. 2020 May 19;13:4445-4455.|Oncol Lett. 2021 Jan;21(1):31.|PLoS One. 2023 May 18;18(5):e0283943.|PLoS Pathog. 2023 Feb 3;19(2):e1011126.|Protein Cell. 2022 Feb 26.|Research Square Preprint. 2020 Dec.|Research Square Print. 2022 Aug.|Research Square Print. November 29th, 2022.|Rheumatology. 2022 Aug 19;keac467.|Small Methods. 2020, 2000483.|SSRN. 2023 Feb 27.|Stem Cells Dev. 2021 Sep 5.|Virus Genes. 2022 Mar 7.|Acta Biochim Biophys Sin. 2021 Feb 1;gmaa180.|Adv Mater. 2020 Nov;32(45):e2003708.|Andrology. 2020 May;8(3):663-670.|Arch Toxicol. 2019 Jun;93(6):1697-1712. |Biochem Pharmacol. 2017 Aug 15;138:49-60. |Biomaterials. 2021 Jul;274:120850.|Biomed Pharmacother. 2019 Jul;115:108875.|Bone Res. 2023 Aug 16;11(1):45.|Brain Res Bull. 2020 Nov;164:146-156.|Cancer Cell. 2020 Sep 14;38(3):350-365.e7.|Cancers (Basel). 2022 Mar 17;14(6):1538.|Cell Death Dis. 2021 Oct 2;12(10):902.|Cell Death Dis. 2021 Oct 9;12(10):925.|Cell Metab. 2023 Jan 3;35(1):101-117.e11.|Cell Metab. 2023 Jul 11;35(7):1132-1146.e9.|Cell Physiol Biochem. 2017;44(4):1381-1395.|Cell Physiol Biochem. 2018;51(4):1566-1583.|Cell Rep. 2019 Oct. |Dissolut Technol. 2020, 27(1):36-44.|EMBO Rep. 2022 Apr 4;e54147.|Endocrinology. 2018 May 1;159(5):2008-2021.|Exp Mol Med. 2019 May 22;51(5):57. |Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Front Pharmacol. 2016 Oct 20;7:390.|Front Pharmacol. 2020 Jul 31;11:1038.|iScience. 2023 Jan.|J Biol Chem. 2020 Apr 3;295(14):4451-4463. |J Cell Mol Med. 2017 Dec;21(12):3322-3336.|J Cell Mol Med. 2019 Sep;23(9):6048-6059. |J Neuroinflammation. 2022 Jan 29;19(1):25.|Life Sci. 2019 Sep 1;232:116622.|Mech Ageing Dev. 2020 Oct;191:111347.|Mol Cell Proteomics. 2017 Jul;16(7):1324-1334.|Mol Neurobiol. 2017 Jul;54(5):3327-3341.|Mol Oncol. 2017 Aug;11(8):1035-1049.|Mol Oncol. 2017 Oct;11(10):1475-1492. |Nat Commun. 2019 Feb 6;10(1):620.|Nature. 2023 Sep;621(7977):188-195.|Neuropharmacology. 2020 Mar 15;165:107816.|Onco Targets Ther. 2020 May 4;13:3777-3788. |Patent. US20210128693A1.|Pathogens. 2021, 10(3), 283.|Redox Biol. 2023 Jun 15, 102786.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2023 Jul 24.|Signal Transduct Target Ther. 2020 May 20;5(1):56.|Signal Transduct Target Ther. 2023 Mar 6;8(1):95.|Spine (Phila Pa 1976). 2019 Aug 1;44(15):E865-E872. |Transl Stroke Res. 2022 Jul 19.|Virus Res. 2023 Jun 7;333:199139.
References
– [1]Soraya H, et al. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacol Rep. 2012;64(6):1476-84.|[2]Quaile MP, et al. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol. 2010 Mar 15;243(3):340-7.|[3]Xue J, et al. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis. Reproduction. 2013 Aug 21;146(4):397-406.|[4]Otto M, et al. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab. 2003 May;5(3):189-94.|[5]Avci CB, et al. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14(2):765-8.
CAS Number
– 657-24-9
Molecular Weight
– 129.16
Compound Purity
– 99.98
SMILES
– NC(NC(N(C)C)=N)=N
Clinical Information
– Launched
Research Area
– Cancer; Metabolic Disease; Cardiovascular Disease
Solubility
– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 50 mg/mL (ultrasonic)
Target
– AMPK;Autophagy;Mitophagy
Isoform
– AMPK
Pathway
– Autophagy;Epigenetics;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
